HeartFlow Inc. Chief Executive Officer John C.M. Farquhar sold 27,230 ordinary shares on August 21, 2026, for a total of $1.36 million at $50 per share, according to regulatory filings. The disposal was executed under a Rule 10b5-1 trading plan adopted by Farquhar on September 12, 2025, and left him with 360,814 shares directly held.
The transaction occurred as HeartFlow’s stock traded near its 52-week high of $51.19, following an 117% gain over the prior six months. After-hours quotes showed the shares around $49.75 to $49.89.
HeartFlow reported adjusted losses of $0.07 per share in the second quarter of 2026, exceeding Wall Street’s consensus estimate of a $0.19 loss. Revenue reached $64.1 million, up 48% year-over-year and surpassing both Stifel’s projection of $56.7 million and the consensus estimate of $56.6 million. Growth was driven by increased demand for coronary artery disease diagnostics and expansion in plaque and FFRCT-related services.
In response to the results, Stifel raised its price target for HeartFlow to $45 from $40 while maintaining a buy rating. Analysts at Stifel had previously noted the stock as appearing overvalued relative to its fair value.
